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Abstract
Background
The C9ORF72 expansion is one of the most common genetic etiologies observed with
behavioural variant frontotemporal dementia (bvFTD). Revised diagnostic criteria for
bvFTD (FTDC) were recently introduced but only a few studies have evaluated the accuracy
of these criteria.
Objective
The objective of the study was to evaluate the applicability of the FTDC criteria and assess
the psychiatric history of these patients.
Methods
The study examined 36 patients carrying the C9ORF72 expansion and suffering from
bvFTD (N = 32) or from bvFTD with motor neuron disease (bvFTD-MND, N = 4). Neuropsy-
chological, neuropsychiatric, structural brain imaging and PET/SPECT data were
evaluated.
Results
We found 0.75 sensitivity (SD 0.44, 95%CI 0.57–0.87) for possible bvFTD and 0.64 (SD
0.44, 95%CI 0.57–0.87) for probable bvFTD. The sensitivity was even higher in bvFTD
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patients without MND, i.e., 0.81 for possible bvFTD and 0.69 for probable bvFTD. PET/
SPECT was normal in 17.6% of scanned patients with bvFTD. A history of psychiatric symp-
toms (psychotic and/or mood symptoms) was detected in 61% of cases.
Conclusions
The FTDC possible and probable bvFTD criteria seem to identify the majority of the
C9ORF72 expansion carriers with bvFTD, even though they exhibit only a limited number of
behavioral criteria but a significant amount of psychiatric symptoms. The presence of a nor-
mal PET/SPECT does not exclude the possibility the C9ORF72 associated bvFTD.
Introduction
Frontotemporal lobar degeneration (FTLD) is a clinically, genetically and neuropathologically
heterogeneous group of progressive syndromes especially affecting the frontal and temporal
brain regions. FTLD can be separated into three major clinical subgroups. 1) The behavioural
variant frontotemporal dementia (bvFTD) is characterized by personality changes, social dys-
function and executive deficit; the other two forms are language variants; 2) semantic variant
primary progressive aphasia (svPPA) and 3) nonfluent variant primary progressive aphasia
(nfvPPA). About 15% of patients with FTLD also develop concomitant motor neuron disease
(MND) [1]. On the other hand, approximately 15% of the patients with amyotrophic lateral
sclerosis develop FTLD [2].
The hexanucleotide repeat expansion in chromosome 9 open reading frame 72 (C9ORF72)
has been claimed to be present in the majority of familial FTLD and MND cases [3,4]. In Fin-
land, the frequency of the C9ORF72 expansion associated FTLD is among the highest in the
world and is present in nearly 50% of familial Finnish FTLD cases [4,5].
Rascovsky and colleagues noted that Neary’s 1998 consensus criteria for bvFTD [6] were
somewhat out-of-date [7]. Thus, revised criteria for bvFTD were introduced in 2011 by the
International Behavioural Variant FTD Criteria Consortium (FTDC), to meet these criticisms
[8]. However, the sensitivity of these new criteria has been evaluated in only a few studies. In
two neuropathological confirmed studies (total number of patients N = 293), the sensitivity for
detecting possible bvFTD varied between 0.85–0.95 and for probable bvFTD between 0.75–
0.85 [8,9]. In a small (N = 30) clinical diagnosis based study [10] the sensitivity as high as 1.00
for possible bvFTD and that of 0.60 for probable bvFTD were detected, but it is possible that
these values may be overestimates due to selection bias i.e. the inclusion of patients among
whom the disease was already clearly evident. A specific C9ORF72 core phenotype has been
postulated with early behavioural symptoms, early psychiatric contacts and a high frequency of
neuropsychiatric symptoms [11–13]. However, the revised FTDC in bvFTD patients with the
C9ORF72 expansion has been evaluated in only one small study (n = 10) [14] which reported
low sensitivity estimates i.e. 0.60 for possible bvFTD and 0.38 for probable bvFTD.
Since the phenotype of the C9ORF72 expansion carriers as well as their core clinical symp-
toms in bvFTD may differ from those of the other bvFTD patients, we assessed the sensitivities
of the FTDC possible and probable bvFTD criteria and evaluated the phenotype in the light of
these criteria in 36 Finnish bvFTD patients carrying the C9ORF72 expansion.
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Materials and Methods
Standard protocol approvals, registrations, and patient consents
The ethics committees of Kuopio University Hospital and Oulu University Hospital approved
the research protocol in accordance with the principles of the Declaration of Helsinki. Written
informed consent was obtained from all the participants.
Participants
We identified 43 patients with the C9ORF72 expansion from the memory outpatient clinics of
Kuopio University Hospital and Oulu University Hospital. Individuals with language variant
(s) (N = 7) were excluded. Thus, the final cohort consisted of 36 patients presenting clinical fea-
tures for bvFTD, i.e. 32 patients with bvFTD (N = 32) and four with bvFTD-MND. The age
range was 44–76 years at the time of the first symptoms, 44% (N = 16) were males. BvFTD pre-
sented before MND in three out of four cases.
Clinical review
All C9ORF72 expansion carriers were evaluated by a neurologist specializing in memory dis-
eases (PH, AMR, and VM). The age at the onset of symptoms and data on behavioural symp-
toms were registered systematically. Clinical and neuropsychiatric criteria were evaluated
during the diagnostic procedure. We had only two sib pairs in this study and both of the sib
pairs were referred to neurological examination independently without knowing that there
were FTLD cases in their family. The clinical data was compared against FTDC criteria [8].
The overall functional decline over the time was evaluated from all the patient records. Data on
neuropsychological evaluation was available from 33 patients. Deficits in executive tasks com-
bined with relative sparing of memory and visuospatial functions were accepted as positive
neuropsychological findings for bvFTD. Structural brain imaging was conducted in all patients
(MRI = 17, CT = 7, both MRI and CT = 12) and analyzed visually by an experienced neuroradi-
ologist. SPECT or PET was done in 17 patients and analysis was based on visual reads. The
presence of frontal and/or anterior temporal atrophy in MRI and/or CT or hypoperfusion fron-
tally and/or anterior temporally in PET/SPECT was accepted as a positive neuroimaging result
for FTLD. Psychiatric assessment was done according to prevailing clinical practice by using
the concurrent diagnostic criteria, the period spanning few decades. The symptoms in psychi-
atric records were carefully re-checked by the experienced senior psychiatrist (HKH). Results
were categorized into mood (affective) disorders and psychotic (schizophrenia, schizotypal and
delusional) disorders.
Genetic analyses
The C9ORF72 expansion (>40 repeats) was analyzed using the repeat-primed polymerase
chain reaction assay [4].
Statistical analyses
All the statistical analyses were performed with SPSS 19. The survival of the patients was ana-
lyzed with the Kaplan-Meier test. Statistical analysis was 2-tailed and p<0.05 was considered
statistically significant.
Results
The demographic features as well as onset/duration of the patients are presented in Table 1.
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When the total cohort, i.e. 36 patients with the C9ORF72 expansion, was assessed 75% of
the patients (N = 27) met the FTDC criteria for possible bvFTD (0.75 sensitivity, SD 0.44, 95%
CI 0.57–0.87) and 64% (N = 23) met the probable bvFTD criteria (0.64 sensitivity, SD 0.49,
95%CI 0.46–0.79) (Fig 1). If we assessed only pure bvFTD (N = 32), the sensitivity of the possi-
ble bvFTD criteria was 0.81 (SD 0.40, 95%CI 0.63–0.92) and sensitivity of the probable bvFTD
criteria was 0.69 (SD 0.47, 95%CI 0.50–0.83), whereas these figures for bvFTD-MND (N = 4)
Table 1. Characteristics of the study participants.
Years
Mean (SD) Range 95%CI
Age at the onset of the symptoms 59.3 (6.6) 44–76 57.1–61.3
Age at the diagnosis 61.2 (6.5) 46–79 59.1–63.4
Duration of the symptoms to diagnosis 2.1 (1.7) 0–7 1.5–2.6
Age at the death (N = 18) 67.1 (6.5) 56–81 63.9–70.3
Duration from the onset to death
Total cohort 6.7 (3.9) 1–13 4.8–8.7
Pure bvFTD without MND (N = 14) 7.8 (3.8) 1–13 5.6–10.0
bvFTD with MND (N = 4) 3.0 (0)
Ages, standard deviations (SD), ranges and 95% conﬁdential intervals of characteristics of the study
participants (N = 36).
doi:10.1371/journal.pone.0131817.t001
Fig 1. Flow chart of the study. Thirty-six patients with the C9ORF72 expansion were examined. Seventy-five percent (N = 27) of the study participants met
the possible FTDC criteria and 64% (N = 23) met the probable FTDC criteria. Altogether 25% did not meet FTDC possible criteria. Seventy-eight percent of
them (N = 7) had positive neuroimaging result and 22% (N = 2) had negative neuroimaging result for FTD.
doi:10.1371/journal.pone.0131817.g001
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were both only 0.25. All of the cases suffered from one or more symptoms of FTLD at the time
of diagnosis.
The mean number of behavioural and cognitive criteria of possible bvFTD in the total
cohort was 3.19 (SD 1.26, 95%CI 2.77–3.62, range 1–6) (Figs 2 and 3). In pure bvFTD patients
without MND, the mean number of possible bvFTD features was 3.38 (SD 1.2, 95%CI 2.95–
3.80, range 1–6), while in FTD-MND patients, the number of possible bvFTD features was
only 1.75 (range 1–3). All bvFTD-MND cases displayed a positive neuropsychological profile
for bvFTD, but behavioral changes were absent.
When the neuroimaging and functional decline criteria (FTDC possible bvFTD criteria
apart from behavioural features included in the probable bvFTD criteria) were examined, these
criteria achieved a slight improvement in the sensitivity for C9ORF72 expansion carriers i.e.
81% (N = 29) of the patients were found to be positive with these criteria (0.81 sensitivity, SD
0.40, 95%CI 0.63–0.91). However, neuroimaging (PET/SPECT and MRI or CT) alone exhibited
the highest sensitivity (0.86 sensitivity, SD 0.35, 95%CI 0.70–0.95). MRI or CT criteria were
fulfilled in 26 out of 36 cases (0.72 sensitivity) and PET/SPECT in 14 out of 17 cases (0.82 sensi-
tivity). A diffuse cortical and central atrophy without frontal or temporal predominance was
detected in eight cases that did not fulfill the MRI criterion and two remaining cases had
Fig 2. Frequency of behavioural and cognitive symptoms in patients with theC9ORF72 expansion (%). The numbers at the end of the bars represent
percentage frequencies. Neuropsychological examination was done to 32 study subjects out of 36.
doi:10.1371/journal.pone.0131817.g002
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normal brain MRI imaging. A bilateral parietal hypoperfusion in PET scanning was detected in
one case who did not fulfill PET criterion and PET revealed normal in two of cases.
Psychiatric symptoms were also evaluated in all of the cases. The majority of the patients
(61.1%; N = 22) were found to be suffering from these symptoms. Psychotic symptoms without
mood symptoms were detected in 30.6% (N = 11) of the patients; 11.1% of the patients (N = 4)
displayed only mood symptoms, while 19.4% of the cases (N = 7) experienced both psychotic
and mood symptoms. The mean delay from the psychiatric symptoms to diagnosis of bvFTD
was 4.6 years (95%CI 0.8–8.4, SD 8.5). In spite of one patient with 40 years of progressive disor-
der, the delay was less than ten years for the others.
Altogether 25% of the patients (N = 9) did not meet the FTDC criteria for possible bvFTD.
This subgroup consisted of three patients with FTD-MND and six with pure bvFTD. Their
mean age was at the onset of symptoms 56.6 years (SD 6.4, 95%CI 51.6–61.5, range 44–66) and
at the diagnosis 59.3 years (SD 6.7, 95%CI 54.2–64.5, range 46–69), while being 60.2 years (SD
6.5, 95%CI 57.7–62.8, range 46–76) and 61.9 years (SD 6.5, 95%CI 59.3–64.4, range 48–79)
among the patients fulfilling the criteria (N = 27), respectively. In addition, the mean number
of possible bvFTD features among the patients that didn’t meet the possible bvFTD criteria
was 1.56 (SD 0.5, 95%CI 1.15–1.96, range 1–2) and all of them showed symptoms of executive
dysfunction in the neuropsychological examination. Apathy or inertia was present in four of
them and one patient suffered from disinhibition, but none of the other possible bvFTD criteria
were fulfilled by any of them. However, 77.8% of these cases (N = 7) presented with a positive
neuroimaging result for FTLD (Fig 1) and 66.7% of these cases (N = 6) were positive for both
Fig 3. Cumulative percentage of possible features of the FTDC criteria (%) in patients with theC9ORF72 expansion. The numbers at the end of the
bars represent cumulative percentage frequencies of possible bvFTD features. All the study participants had at least one possible feature and 5.6% had all
the six features.
doi:10.1371/journal.pone.0131817.g003
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cognitive decline and neuroimaging. Psychiatric symptoms were present in 55.6% (N = 5) of
the cases.
The PET/SPECT was normal in 17.6% of the scanned individuals (three out of 17 patients)
and thus it did not meet the PET/SPECT criteria for probable bvFTD. All these cases suffered
from pure bvFTD without MND. Their mean age at onset (53.7 years, SD 1.5, 95%CI 49.9–
57.5, range 52–55) and at time of death (63.5 years, SD 2.1, 95%CI 44.4.-82.6, range 62–65)
were significantly younger compared to all patients (Table 1). Their mean number of possible
bvFTD features was 3.3 (SD 1.5 95%CI -0.46–7.13, range 2–5) and in addition, psychiatric
symptoms were prevalent in all these cases. On the other hand, structural brain imaging indi-
cated bvFTD in all thesePET/SPECT negative cases. The mean duration of the disease from
onset of symptoms to PET/SPECT scanning was 2.0 years among the PET/SPECT negative
cases while the mean duration of the disease was 1.6 years among the PET/SPECT positive
cases.
The mean age at death in the total cohort was 67.1 years (N = 18, SD 6.5, 95%CI 6.39–70.3,
range 56–81).
Discussion
The clinical diagnosis of bvFTD is rather challenging and the new validated criteria for bvFTD
have been recently proposed [8]. However, the sensitivity of these criteria has been evaluated in
only a few studies. In the present study, we investigated the accuracy of FTDC criteria in a
cohort of bvFTD and bvFTD-MND patients with the C9ORF72 expansion.
We found that the sensitivity of FTDC criteria among all patients (including bvFTD and
bvFTD-MND) was 0.75 for possible bvFTD and 0.64 for probable bvFTD. However, the sensi-
tivity was even higher (0.81 for possible and 0.69 for probable) among the patients with pure
bvFTD i.e. excluding those with features of MND. These sensitivities are clearly higher com-
pared to a previously found in a smaller study of ten patients with the C9ORF72 expansion (i.e.
0.60 for possible bvFTD and 0.38 for probable bvFTD) [14]. Instead, our results more closely
resembled those for neuropathologically-confirmed bvFTD cases. In large, neuropathologi-
cally-confirmed bvFTD case series assessing FTDC criteria, sensitivities were only slightly
higher i.e. 0.85 for possible and 0.75 for probable bvFTD [8] than in the present study. Still,
another large autopsy-based study did suggest even higher sensitivities, i.e. 0.95 for possible
bvFTD and 0.85 for probable bvFTD [9].
In the present study, the number of the patients with FTD-MND phenotype was limited
and the sensitivity of FTDC criteria was very low in these cases (0.25). This low sensitivity in
FTD-MND cases may be attributable to the extremely rapid disease progression, short survival
of the patients and limited number of cases. The neuropsychiatric symptoms may also be diffi-
cult to recognize in patients with bulbar symptoms. Our results are in line with a previous
study in which the C9ORF72 expansion carriers with bvFTD-MND tended to have reduced
sensitivity for FTCD in comparison to non-carriers [15].
The mean number of the cognitive or behavioural criteria found in the present cohort was
three (3.19). The relatively high probable bvFTD sensitivity in our study may be explained by
the high sensitivity of neuroimaging when combined with cognitive and behavioural criteria.
Our findings may even indicate that the actual sensitivity of neuroimaging (including MRI or
CT combined with PET/SPECT if available) could be even higher (0.86) than the FTDC criteria
sensitivity for possible bvFTD (0.75). When examining these values more closely, it is interest-
ing to note that the sensitivity for MRI alone was 0.72 and for PET/SPECT 0.82, which is paral-
lel with a recent study by Snowden and colleagues [16]. This finding is exciting because a
previous study claimed that there were very low sensitivities for MRI (0.13) and PET (0.50)
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among the C9ORF72 expansion carriers [14]. However, those findings may have been some-
what biased due to small size of the cohort (N = 10). Quite contrary, the sensitivity of SPECT
was 0.94 among the C9ORF72 expansion carriers (N = 16) in another study [16].
The core phenotype in the bvFTD patients with the C9ORF72 expansion seems to differ
from neuropathologically-confirmed bvFTD cases (i.e. without data on their C9ORF72 status),
while the number of diagnostic criteria seems to be lower in patients with the C9ORF72 expan-
sion. This argument is supported by the finding that in neuropathological and clinical cohorts,
the sensitivity of each possible feature is on average very high (over 50%) except for hyperoral-
ity [7,9,10,17,18] while Devenney and colleagues found the mean number of possible bvFTD
features to be 4.2/6 in patients with the C9ORF72 expansion which is slightly higher compared
to our results (3.19/6 features). Executive dysfunction in the neuropsychological profile was
detected in all of the patients and this was found even in the early stages of the disease or in
cases that did not fulfill the criteria for bvFTD. Disinhibition, apathy/inertia and early persever-
ation were also common symptoms, while early loss of sympathy or empathy was rare. The rel-
atively poor sensitivity (0.33) for early loss of sympathy or empathy has also been detected in a
previous neuropathologically-confirmed (N = 135) cohort from UK and Australia, [17]. How-
ever, when evaluating the absence of early sympathy or empathy, cultural differences may play
a role. Thus, the detection of different symptoms may indeed be linked to the cultural environ-
ment, e.g. with regard to emotional issues like the loss of empathy or sympathy. This is the first
study from Finnish patients and there is no previous data which would have assessed FTDC
criteria in either the Nordic or Baltic countries.
Surprisingly, PET/SPECT was normal in a substantial proportion (17.6%) of the patients.
Thus, a normal finding in SPECT cannot exclude the possibility that the patient has the
C9ORF72 associated bvFTD. This finding is supported also in previous studies of FTD patients
with the C9ORF72 expansion (N = 10 and 32) [14,16]. Interestingly, the PET/SPECT negative
cases in the present study tended to have a considerably earlier onset of symptoms and earlier
death, more psychiatric symptoms and more possible features of FTDC criteria, but their num-
ber was too low to draw any firm conclusions. None of the PET/SPECT negative individuals
suffered from MND. The time of PET/SPECT scanning did not affect the results, because these
scans were conducted at clearly later clinical disease stages in the PET/SPECT negative cases
than in their PET/SPECT positive counterparts. Furthermore, structural brain MRI imaging
had its limitations with 0.72 sensitivity, highlighting the need to combine structural (MRI or
CT) and functional (PET/SPECT) neuroimaging, which resulted in a surprisingly high sensitiv-
ity (0.86).
To date, this is the largest genetically confirmed cohort assessing the FTDC revised criteria
in bvFTD patients with the C9ORF72 expansion. Patients carrying the expansion seem to
fulfill the FTDC possible and probable bvFTD criteria rather well, but the sensitivity was
lower as compared to that obtained in neuropathologically-confirmed bvFTD cohorts. Execu-
tive dysfunction seems to be a core feature in all of the patients and psychiatric symptoms are
abundant, but the number of the behavioral symptoms is fewer than encountered in neuro-
pathologically-confirmed cohorts without genetic confirmation.
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